Estelle Vester-Blokland’s Post

At @Bristol Myers Squibb, we are all in on #TargetedProteinDegradation (TPD) and its potential for patients. As one of our differentiated research platforms, we’re expanding on our legacy in TPD by exploring potential new options across a broad range of diseases. We had great discussions about these advancements during our annual European Scientific Innovation Summit this week. You can learn more about our efforts in TPD here: Science Firsthand: The pathway to drug discovery – Bristol Myers Squibb (bms.com) #BMS_Employee, #EUScientificInnovationSummit

Big News in the Biotech World! 🚀 Biohaven has made headlines by linking their drug troriluzole to a significant slowing of disease progression in spinocerebellar ataxia. This breakthrough comes after an earlier phase 3 failure, showcasing the importance of perseverance in the clinical research industry. 🧬 After rigorous analysis and comparison to external real-world data, patients on troriluzole showed a 50-70% slower progression rate. To put this into perspective, this slowing represents a 1.5 to 2.2-year delay in disease progression over the three-year trial. This is a huge win for both patients and the biotech community. 💪 Biohaven plans to seek FDA approval in Q4, with hopes to commercialize the treatment in the U.S. next year. This is a reminder to all of us to stay resilient and keep pushing boundaries. 🌍 #Biotech #ClinicalResearch #InnovationsInHealthcare #Biohaven

Take a look at the Spotlight interview with Eduardo Jule, PhD in the September AAPS LBDDS Community Newsletter. Dr. Jule, our esteemed trainer, will be leading the upcoming "Lipid-Based Formulations" course. With over 20 years of experience in lipid-based drug delivery and pharmaceutical development, this training offers an unmatched opportunity to gain valuable insights! 💡 Check out all Lipid Based Formulations news in the newsletter below! 👇 #interview #Newsletter #LipidBasedFormulations #SymmetricTraining

Join senior execs including Steve Rosenberg, Bruce Hellman, Florence Mowlem, PhD, Andrea Valente and Don Butler at #pharma and #lifesciences events this fall.  Learn how we’re guiding #pharma and #biotech sponsors, sites and patients to demand more from #clinicalresearch technology with modern #eCOA #ePRO and best-in-class #eConsent to improve #clinicaltrials and #realworldstudies. https://lnkd.in/g_j4kDwn DPHARM: Disruptive Innovations to Modernize Clinical Research Society for Clinical Research Sites (SCRS) Society for Clinical Data Management (SCDM) Outsourcing in Clinical Trials Event Series CNS Summit

Remember to put our next webinar in your diary! All details below ⬇

**Please note that we have had to postpone this webinar due to external events, we will announce the new date shortly, stay tuned!** Join us for a discussion with the authors of the recently published article ‘Making Good Decisions in Early Drug Discovery’ (Drug Discovery Today June 2024). The conversation will focus on the critical elements of Decision Framing, which are key to enabling collaborative conversations and alignment with early drug discovery teams and the development of a clear decision roadmap. The approach was developed to address the challenges of decision making in drug discovery research in the face of uncertainty. The concept and tools associated with Decision Quality provide a helpful frame for team-based strategy development, scientific conversation and qualitative evaluation of plan options. During this webinar, we will discuss and answer the following questions: ✔ How is Decision Quality used to support early drug discovery? ✔ Which Decision Framing tools facilitate the development of alternative strategies and the Decision Roadmap? Registration Link: https://lnkd.in/gbQzdb9w #DecisionMaking #UncertaintyAnalysis #OnlineCourse #ProfessionalDevelopment #DecisionScience #DecisionQuality

Europe: Where is the drug discovery innovation? Thanks to a prestigious academic legacy, Europe has long been a dominant region for life sciences. In this article, DDW's Diana Spencer highlights several prominent hotspots that are taking the lead on advancing European drug discovery and development. https://lnkd.in/e-VhPQkv #DrugDiscovery #Innovation #LifeSciences

Today, Biotrial enrolled the first subjects of a new phase I bioequivalence study. The study features a Crossover design with 75 volunteers hospitalized for 14 days in Biotrial's state-of-the-art Phase I facilities. With over 35 years of experience in conducting well-controlled clinical trials, our high recruitment capabilities enable us to quickly mobilize a large number of volunteers tailored to your study's needs. Our teams offer personalized solutions for your drug development initiatives, ensuring efficient and timely study progression. #ClinicalTrials #PhaseI #Drugdevelopment

On Rare Disease Day, we send our congratulations to the PharmAust team on the recently released top line results from their Phase 1 MEND study, assessing monepantel as a potential therapy for Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS). This work has found that "monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio®", while "preliminary efficacy data shows a 58% reduction in the rate of disease progression for Cohort 2 (High Dose) using the FDA primary efficacy endpoint, ALSFRS-R". More detail on these results can be found in the below presentation, delivered by PharmAust CEO, Dr Michael Thurn. Alithia Life Sciences is extremely proud to be associated with this groundbreaking research and we look forward to supporting future phases of this study when they commence in the second half of 2024. #rarediseaseday #raredisease #rarediseases #motorneuronedisease #mnd #als #clinicalresearch #clinicaltrial #medicalresearch #scientificresearch #medicaltreatment

🌟 NEWS: We have launched the clinical white paper! 🚀 In drug development, one of the most critical phases is the transition from preclinical stages to human trials. This involves moving from lab and animal studies to testing the drug's safety, dosage, and initial efficacy in humans. Professional planning and meticulous implementation at this stage are essential. Effective management streamlines subsequent clinical phases minimizes risks, addresses regulatory hurdles, and optimizes resources, thereby increasing the chances of success. This white paper focuses on three major factors that are essential for managing a smooth transition from preclinical to clinical research. The goal is to commence the clinical development program on time and ensure it is adequately designed to meet all planning targets. Check out our newly launched white paper: https://lnkd.in/e7CK3en8 and connect with our author, Wolfgang Timmer, if you have any questions or would like to discuss your project with us! #NUVISAN #preclinical #clinicaltrial #FIH